Celldex (CLDX) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks rattled, Treasuries rally after Israel attacks Iran
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Oil steadies after surge following reported Israeli attack on Iran
- Reports of Israeli attack on Iran spark rush to Swiss franc and yen
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Celldex Reports Second Quarter 2016 Results
August 8, 2016 4:02 PM EDTHAMPTON, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported business and financial highlights for the second quarter ended June 30, 2016.
Celldex continues to build one of the most robust pipelines in immuno-oncology, most recently advancing CDX-014 into the clinic in renal cell carcinoma, said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. In collaboration with our investigators, we also presented a significant body of data in the second quarter with eight presentations across both AACR and ASCO that spoke to the broad utility of our product... More
